Key result
Indirect costs associated with stroke and bleeding in atrial fibrillation were highest for hemorrhagic stroke and intracranial hemorrhage, increasing to 30-50% of total costs 2 years post-event.
Why the study?
Economic consequences associated with the rise in nonvitamin K antagonist oral anticoagulant use on a societal level remain unclear.
What are the societal costs associated with stroke, bleeding, and monitoring in patients with atrial fibrillation?
Systematic Review (n=14)
What are the societal costs associated with stroke, bleeding, and monitoring in patients with atrial fibrillation?
Indirect societal costs of stroke and bleeding in atrial fibrillation are substantial, particularly 2 years post-event, highlighting the broader economic impact of these complications.
Long-term indirect costs from hemorrhagic events in AF merit inclusion in economic models and policy; extends direct-cost analyses to capture sustained societal burden.
Aim: Economic consequences associated with the rise in nonvitamin K antagonist oral anticoagulant use on a societal level remain unclear. Materials & methods: Evidence from the past decade on the societal economic burden associated with stroke, bleeding and international normalized ratio monitoring in atrial fibrillation was collected and summarized through a systematic literature review. Results: There were 14 studies identified that reported indirect costs, which were highest among patients with hemorrhagic stroke and intracranial hemorrhage. The contribution of indirect costs to the total was marginal during acute treatment but substantially increased (30–50%) 2 years after stroke and bleeding events. Conclusion: Limited data were available on societal costs in atrial fibrillation and further research is warranted.
No takes yet. Share an insight, caveat, or question.
Martin et al. (2019) conducted a systematic review in Atrial fibrillation (n=14). Stroke, bleeding, and INR monitoring was evaluated on Societal economic burden and indirect costs. Indirect costs associated with stroke and bleeding in atrial fibrillation were highest for hemorrhagic stroke and intracranial hemorrhage, increasing to 30-50% of total costs 2 years post-event.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: